Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 28 Sep 2017 Status changed from not yet recruiting to recruiting.
- 15 Sep 2017 Planned initiation date changed from 15 Aug 2017 to 1 Oct 2017.
- 11 Aug 2017 New trial record